Several studies showed that cardiovascular health in patients with diabetes might significantly benefit from antihyperglycaemic medications, such as glucagon-like-peptide 1 (GLP1) agonists (194), dipeptidyl peptidase 4 (DPP4) inhibitors (195), and sodium-glucose cotransporter-2 inhibitors (SGLT2i) (196). This evidence concerns the gene DPP4 and diabetes mellitus.